Skip to main content
. 2023 May 24;7(16):4302–4314. doi: 10.1182/bloodadvances.2023009903

Table 1.

Telomere-targeted therapies in development

Compound Mechanism Current study phase Indication(s)
BIBR1532 Small-molecule inhibitor of hTERT Preclinical Solid and hematologic malignancies
UV1 hTERT peptide vaccine Phase 2 Melanoma and NSCLC
GX301 hTERT peptide vaccine Phase 2 Prostate cancer
AST-1 hTERT-directed dendritic cell Phase 1 AML and prostate cancer
VAC2 hTERT-directed dendritic cell Phase 2 NSCLC
IME Oligonucleotide complementary to hTERT template Phase 3 MDS and MF